Filing Details

Accession Number:
0001104659-20-010942
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-05 06:05:10
Reporting Period:
2020-01-31
Accepted Time:
2020-02-05 06:05:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1477845 Annovis Bio Inc. ANVS Pharmaceutical Preparations (2834) 262540421
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1490045 Whelan, Jr. Robert M. C/O Annovis Bio, Inc.
1055 Westlakes Drive, Suite 300
Berwyn PA 19312
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-31 25,000 $6.00 25,000 No 4 P Direct
Common Stock Acquisiton 2020-01-31 59,524 $0.00 84,524 No 4 C Direct
Common Stock Acquisiton 2020-01-31 11,176 $4.80 95,700 No 4 C Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 C Direct
No 4 C Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-1 Preferred Stock Disposition 2020-01-31 83,333 $0.00 59,524 $0.00
Common Stock Convertible Note Disposition 2020-01-31 11,176 $4.80 11,176 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
  2. Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
  3. The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).